Post on 01-Apr-2018
transcript
PREGABALIN
Pre-Review Report
Agenda Item 5.1
Expert Committee on Drug Dependence
Thirty-ninth Meeting
Geneva, 6-10 November 2017
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 2 of 30
Contents
Acknowledgements.................................................................................................................................. 4
Summary...................................................................................................................................................... 5
1. Substance identification ....................................................................................................................... 7
A. International Nonproprietary Name (INN).......................................................................................................... 7 B. Chemical Abstract Service (CAS) Registry Number .......................................................................................... 7 C. Other Chemical Names ................................................................................................................................................... 7 D. Trade Names ....................................................................................................................................................................... 7 E. Street Names ....................................................................................................................................................................... 9 F. Physical Appearance ....................................................................................................................................................... 9 G. WHO Review History ....................................................................................................................................................... 9
2. Chemistry ................................................................................................................................................... 9
A. Chemical Name .................................................................................................................................................................. 9 B. Chemical Structure ........................................................................................................................................................... 9 C. Stereoisomers ...................................................................................................................................................................... 9 D. Methods and Ease of Illicit Manufacturing ........................................................................................................... 9 E. Identification and Analysis ........................................................................................................................................ 10
3. Ease of Convertibility Into Controlled Substances ...................................................................... 10
4. General Pharmacology ........................................................................................................................ 10
A. Routes of administration and dosage ................................................................................................................... 10 B. Pharmacokinetics .......................................................................................................................................................... 10 C. Pharmacodynamics ....................................................................................................................................................... 11
5. Toxicology ................................................................................................................................................ 12
6. Adverse Reactions in Humans ........................................................................................................... 12
7. Dependence Potential .......................................................................................................................... 14
A. Animal Studies ................................................................................................................................................................. 14 B. Human Studies................................................................................................................................................................. 14
8. Abuse Potential ...................................................................................................................................... 16
A. Animal Studies ................................................................................................................................................................. 16 B. Human Studies................................................................................................................................................................. 16
9. Therapeutic Applications and Extent of Therapeutic Use and Epidemiology of Medical
Use .............................................................................................................................................................. 17
10. Listing on the WHO Model List of Essential Medicines .............................................................. 17
11. Marketing Authorizations (as a Medicinal Product) ................................................................. 17
12. Industrial Use ......................................................................................................................................... 18
13. Non-Medical Use, Abuse and Dependence ..................................................................................... 18
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 3 of 30
14. Nature and Magnitude of Public Health Problems Related to Misuse, Abuse and
Dependence ............................................................................................................................................. 20
15. Licit Production, Consumption and International Trade ......................................................... 22
16. Illicit Manufacture and Traffic and Related Information ........................................................ 22
17. Current International Controls and Their Impact ...................................................................... 22
18. Current and Past National Controls ................................................................................................ 22
19. Other Medical and Scientific Matters Relevant for a Recommendation on the Scheduling
of the Substance ..................................................................................................................................... 22
References ................................................................................................................................................ 23
Annex 1: Report on WHO Questionnaire for Review of Psychoactive Substances for the 39th ECDD: Evaluation of Pregabalin ............................................................................................. 30
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 4 of 30
Acknowledgements
This report has been drafted under the responsibility of the WHO Secretariat, Department of
Essential Medicines and Health Products, Teams of Innovation, Access and Use and Policy,
Governance and Knowledge. The WHO Secretariat would like to thank the following people for
their contribution in producing this review report: Associate Professor Beth Sproule, Toronto,
Canada (literature search, review and drafting), Ms. Dilkushi Poovendran, Geneva, Switzerland
(questionnaire analysis and report drafting) and Dr. Stephanie Kershaw, Adelaide, Australia (review
report editing, questionnaire analysis and report drafting).
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 5 of 30
Summary
Pregabalin is a medication used world-wide in the treatment of partial onset seizures, post-herpetic
neuralgia, diabetic neuropathy, fibromyalgia, spinal cord injury neuropathic pain, and generalized
anxiety disorder. The actions of pregabalin are mediated through binding with high affinity to
alpha-2-delta proteins, which attenuates calcium influx into presynaptic neurons and thereby
blocks the release of neurotransmitters, including the excitatory neurotransmitter l-glutamate.
Most information on the abuse potential of pregabalin comes from therapeutic clinical trial data,
pharmacoepidemiological surveillance, and case reports/anecdotal reports, with only one
published formal human abuse liability study. Euphoria has been noted as an adverse event in
therapeutic clinical trial patients and pharmacokinetic study healthy participants. Evidence from
preclinical and therapeutic clinical trials suggests the development of tolerance to the euphoric
effects. Withdrawal symptoms manifest in some patients following abrupt discontinuation of
pregabalin treatment (e.g., insomnia, headache, nausea, anxiety, sweating and diarrhea). For this
reason it is recommended that patients undergo a short taper period (1 week) when discontinuing
treatment. The one published abuse liability study assessed single doses of pregabalin 75 mg and
150 mg. This low pregabalin exposure in people without psychiatric and substance use disorder
histories was not associated with increased ratings for liking. In a study submitted with the
manufacturer’s New Drug Application in the United States in 2004, a single dose of pregabalin
450 mg was rated similarly to a single dose of diazepam 30 mg on measures of liking in alcohol
and sedative/hypnotic recreational users. This finding contributed to the assignment of pregabalin
to Schedule V of the Controlled Substance Act in the United States.
Epidemiological evidence for pregabalin abuse and dependence has been growing. It is available
from adverse drug reaction reporting databases (representing 3-7% of pregabalin reports) and
drug utilization reviews (with high doses prescribed at rates ranging from 1-10% of patients). In
surveys of substance using populations, 3-68% of respondents endorsed non-prescribed or misuse
of pregabalin. Pregabalin has been detected in urine samples of patients in opioid dependence
treatment (9-12%) and in postmortem toxicological samples, with increasingly higher rates within
drug dependent populations in combination with other substances. The risk of overdose death
from pregabalin alone appears to be low, however, there is concern about the combination of
pregabalin with opioids. Very high maximum daily doses (up to 7500 mg/day) have been
described in published case reports and online anecdotal reports of pregabalin abuse.
From the available evidence, pregabalin clearly has the potential for abuse and dependence. Most
published evidence is relatively recent and the extent to which pregabalin abuse may increase is
not known. There is interest in pregabalin for its use in the treatment of substance use disorders
(e.g., alcohol, benzodiazepine, opioids), however its use for these indications must be balanced
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 6 of 30
with its potential to be abused in this population. Its abuse potential appears lower than for opioids.
Its relative abuse liability compared to other substances, particularly other psychotropic
medications that people may be exposed to therapeutically (for example, benzodiazepines), has
not been well studied.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 7 of 30
1. Substance identification
A. International Nonproprietary Name (INN)
Pregabalin
B. Chemical Abstract Service (CAS) Registry Number
148553-50-8
C. Other Chemical Names
(S)-3-(aminomethyl)-5-methylhexanoic acid; (S+)-3-isobutyl-GABA
D. Trade Names
Lyrica: Argentina; Australia; Austria; Belgium; Bosnia & Herzegovina; Brazil;
Canada; Chile; China; Croatia (Hrvatska); Czech Republic; Denmark;
Ecuador; Egypt; Finland; France; Georgia; Germany; Greece; Hong
Kong; Hungary; Iceland; India; Indonesia; Ireland; Israel; Italy South
Korea; Japan; Latvia; Lebanon; Lithuania; Luxembourg; Malaysia;
Myanmar; Netherlands; New Zealand; Norway; Norway; Oman; Peru;
Philippines; Poland; Portugal; Romania; Russian Federation; Serbia;
Singapore; Slovakia; Slovenia; South Africa; Spain; Sweden;
Switzerland; Thailand; Tunisia; Turkey; United Kingdom; United States;
Vietnam.
Others:
Argentina Axual. Balifibro. Clasica, Dolgenal, Gavin, Kabian,
Linprel, Mystika, Neuristan, Plenica, Prebanal,
Prebictal, Prebien
Bangladesh Gaba-PGabarol, Lyric, Neurega, Neurolin, Neurovan,
PG, Prebalin, Pregaba, Pregaben, Pregadel, Pregan,
Prelin, Pretor, Priga, Xablin, Xil
Bosnia & Herzegowina Epica, Epiron, Pagamax
Canada Apo-Pregabalin, PMS-Pregabalin, Pregabalin Sanis
Health, RAN-Pregabalin, Sandoz Pregabalin, Teva-
Pregabalin
Chile Alivax, Neurum, Plenica, Prebictal, Prefaxil, Pregalex,
Pregalin, Pregobin, Prestat
Colombia Dolica, Martesia, Pregabalina Ecar, Pregabalina MK,
Preludyo
Costa Rica Martesia
Egypt Andogablin, Averopreg, Convugabalin, Dapapalin,
Dragonor, Gablovac, Glonervya, Hexgabalin,
Irenypathic, Kemirica, Lyrineur, Lyrolin, Neuragabalin,
Painica, Pregaba, Pregatrend, Pregavalex, Pregdin
Apex, Serigabtin, Vronogabic
El Salvador Martesia, Pregabateg, Prelyx
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 8 of 30
Equador Neurum, Prebictal, Pregobin
Estonia Brieka, Pragiola, Pregabalin Alvogen, Pregabalin Teva,
Pregagamma, Pregamid
France Pregabaline Sandoz GmbH
Georgia Helimon
Guatamala Martesia, Pregabateg
Honduras Martesia
Hong Kong Apo-Pregabalin
Iceland Pregabalin Krka
India Gabanext, Nuramed, Pevesca, Prebel, Pregaba,
Pregabin, Pregacent, Preganerve, Pregastar, Pregeb-OD,
Prejunate, Preneurolin, Resenz
Indonesia Aprion, Provelyn
Lebanon Gabrika, Plenica
Mexico Dismedox, Gialtyn, Kineptia
Myanmar Maxgalin
Netherlands Lingabat
Nicaragua Martesia
Panama Martesia
Peru Neurum, Prebictal, Pregalex, Pregobin
Poland Pragiola, Pregabalin Pfizer
Portugal Pregabalina Alter, Pregabalina Baldacci, Pregabalina
Cinfa, Pregabalina Farmoz, Pregabalina Gática,
Pregabalina Generis, Pregabalina Jaba, Pregabalina
Kipa, Pregabalina Pentafarma, Pregabalina Pharmakern,
Pregabalina Ratiopharm, Pregabalina Tetrafarma,
Pregabalina Teva, Pregabalina ToLife
Netherlands Pregabaline AET, Pregabaline Aurobindo, Pregabaline,
CFPregabaline Hetero, Pregabaline Krka, Pregabaline
Ranbaxy, Pregabaline Teva, Pregabaline Torrent,
Pregabaline Wockhardt, Pregagamma, Pregamid
Russian Federation Algerika, Pregabalin-Richter
Slovakia Pregabalin Sandoz
Slovenia Ecubalin, Pragiola
South Korea Newrica, Pregalin
Spain Pregabalina Apotex, Pregabalina Cinfa, Pregabalina
Kern Pharma, Pregabalina Stada Genericos, Pregabalina
Tarbis
Switzerland Pregabalin Pfizer, Pregabalin-Mepha
Thailand Pregabalin Sandoz
Turkey Alyse, NeuricaPaden, Pagadin, Regapen, Symra
United Kingdom Lecaent, Rewisca,
Vietnam Gabica, Gablin, Pregobin, Premilin
(Drugs.com 2017)
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 9 of 30
E. Street Names
Gabbies; Budweisers, Bud, Bud light, Fizers
(Millar 2013, DRUGS.ie 2017, Extern 2017)
F. Physical Appearance
White to off-white crystalline solid
G. WHO Review History
Pregabalin has not been previously reviewed by the WHO Expert Committee on
Drug Dependence.
2. Chemistry
A. Chemical Name
IUPAC Name: (3S)-3-(aminomethyl)-5-methylhexanoic acid
CA Index Name: Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)-
B. Chemical Structure
Free base:
(Pfizer, 2016)
Molecular Formula: C8H17NO2
Molecular Weight: 159.23
C. Stereoisomers
Pregabalin is the (S)-(+)-isomer of 3-isobutyl-GABA
D. Methods and Ease of Illicit Manufacturing
No information was found on methods of illicit manufacturing. Published
literature describes enantioselective synthesis methods. (Burk 2003, Yu 2012)
Melting point: 176 - 178 oC
Boiling point: 144 – 147 oC
Solubility: Freely soluble in water (both basic and acidic aqueous solutions)
(ChemSpider 2017, Pfizer 2016)
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 10 of 30
E. Identification and Analysis
Several methods have been developed for identification of pregabalin. This includes
liquid chromatography–tandem mass spectrometry (LC–MS–MS) methods in
human urine (Heltsley 2011) and human serum (Oertel 2009); high-performance
liquid chromatography (HPLC) methods in human serum (Vermeij 2004) and for
capsule contents (Kasawar 2010); a high-performance liquid chromatography –
mass spectrometry (HPLC-MS) method in post-mortem samples (Priez-Barallon
2014); a spectrophotometric method for capsule contents (Bali 2011); and
immunoassay methods for human urine (e.g., ARK 2017).
3. Ease of Convertibility Into Controlled Substances
No information was found on the conversion of pregabalin into other controlled
substances.
4. General Pharmacology
A. Routes of administration and dosage
Pregabalin pharmaceutical products are available to be taken orally.
Capsule strengths: 25, 50, 75, 100, 150, 200, 225, 300 mg
Oral Solution: 20 mg/ml
Dosage (administered orally in 2 – 3 divided doses)
Partial Onset Seizures: Initially 150 mg daily;
Maintenance 150-600 mg daily.
Post-herpetic Neuralgia: Initially 150 mg daily;
Maintenance 150-300 mg daily;
Maximum dosage 600 mg daily.
Diabetic Neuropathy: Initially 150 mg daily;
Maintenance 150-300 mg daily.
Fibromyalgia: Initially 150 mg daily;
Maintenance 150-450 mg daily.
Spinal Cord Injury Neuropathic Pain: Initially 150 mg daily;
Maintenance 150-300 mg daily;
Maximum dosage 600 mg daily.
Generalized Anxiety Disorder: Initially 150 mg daily;
Maintenance 150-600 mg daily.
Dosage needs to be lowered with renal impairment (Clcr <60 mL/minute). (AHFS
2017, Pfizer 2016 Canada, Pfizer 2016 USA, Pfizer 2017 UK)
B. Pharmacokinetics
Pregabalin has a relatively simple pharmacokinetic parameter profile compared to
many psychotropic drugs.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 11 of 30
Absorption: Pregabalin is rapidly and extensively absorbed. Plasma concentrations
peak within 1.5 hours after administration, with oral bioavailability greater than
90% that is independent of dose and frequency of administration. Peak
concentrations and area under the plasma concentration-time curve increase
proportionally with dosage. Food slows the rate of absorption but not the extent of
absorption.
Distribution: Pregabalin is a substrate for system L transporter across the blood-
brain barrier. The apparent volume of distribution of pregabalin following oral
administration is approximately 0.5 L/kg. Pregabalin is not bound to plasma
proteins.
Metabolism: Pregabalin undergoes negligible metabolism. The N-methylated
metabolite accounts for less than 1% of the dose.
Elimination: Pregabalin is eliminated primarily (98%) by renal excretion as
unchanged drug, with elimination proportional to creatinine clearance. Less than
0.1% is eliminated in faeces. The mean half-live of pregabalin is approximately 6
hours (range 4 to 7 hours) and is not dose dependent. Steady-state is reached within
2 days of regular dosing. (Warner 2005, Bockbrader 2010, Schulze-Bonhage 2013)
C. Pharmacodynamics
Pregabalin binds with high affinity to the alpha-2-delta protein – a subunit of
voltage-gated calcium channels located at presynaptic endings of neurons in the
brain and spinal cord. This attenuates Ca2+ flux into neurons, which blocks the
release of neurotransmitters, including the excitatory neurotransmitter l-glutamate.
Endogenous ligands include the amino acids L-leucine, L-isoleucine, and L-valine.
Despite similarities to gamma-aminobutyric acid (GABA), it does not act at GABA
receptors or synapses. Pregabalin has approved indications for the treatment of
partial seizures, post-herpetic neuralgia, diabetic neuropathy, fibromyalgia, spinal
cord injury neuropathic pain and generalize anxiety disorder. It appears that the
therapeutic actions for all of these conditions are mediated through pregabalin’s
actions on the alpha-2-delta protein. It has been suggested that these disorders may
share neuronal hyperactivity in a variety of brain circuits that pregabalin helps to
normalize. Further study on the actions of pregabalin in different brain regions is
needed. The exact mechanism for producing euphoric effects or physical
dependence is not known at this time. (Schulze-Bonhage 2013, Stahl 2013,
Silverman 2008, Taylor 2007)
Pregabalin has been used off-label in the treatment of drug and alcohol withdrawal.
(Freynhagen 2016) Although limited, most evidence is for the treatment of alcohol
and benzodiazepine withdrawal. For example, there have been 3 small randomized-
controlled studies for alcohol withdrawal (Freynhagen 2016); and there are case
reports (Biermann 2007, Oulis 2008a), open-label studies (Oulis 2008b, Bobes
2012, Cho 2014), a prescription database study (Bramness 2010), and one small
randomized controlled trial for the treatment of benzodiazepine withdrawal.
(Hadley 2012)
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 12 of 30
5. Toxicology
Preclinical Acute Toxicology
There were no deaths following administration of single oral doses of pregabalin 5000
mg/kg or single IV doses of 300 mg/kg to mice and rats, nor changes in biochemical
parameters, however, there were observations of hypoactivity, diarrhea and urine staining.
Pregabalin was not genotoxic in vitro, nor in rats in doses up to 2000 mg/kg. (Pfizer
2016)
Preclinical Chronic Toxicology
There was a dose-dependent increase in hemangiosarcomas in 2 strains of mice with 200 to
5000 mg/kg in their diet for 2 years. The exposure was considered to be similar to human
exposure at 600 mg/day. Tumorigenic potential is included in the Warnings and Precaution
section of the product monograph. Skin lesions were seen at exposures equivalent to 2 to 8
times that of human exposure at 600 mg/day, ranging from erythema to necrosis. Ocular
lesions were detected in rats at exposures more than twice those in humans at 600 mg/day.
The following have been observed in animal toxicology studies with exposures from 2 to
69 weeks: ataxia and hypoactivity in rats and monkeys at repeated oral doses ≥ 500 mg/kg;
tail dermatopathy and urine staining in rats ≥ 250 mg/kg and monkeys up to 500 mg/kg;
urinary bladder changes and mortality with pyelonephritis/cystitis in rats at ≥ 250 mg/kg;
reversible platelet count decreases of 14-36% in rats at ≥50 mg/kg in males and ≥ 100
mg/kg in females; no changes in hematology up to 500 mg/kg in monkeys; bone marrow
total nucleated cell decreases 18-44% in rats at 150-1250 mg/kg, with no changes up to 50
mg/kg in rats nor in monkeys; no effects on body weight gain at 50 mg/kg or 150 mg/kg
and no effects on monkeys up to 500 mg/kg; nasal discharge and diarrhea in monkeys at ≥
100mg/kg; and deaths in 3 days in monkeys at doses of 1000 or 2000 mg/kg. (Pfizer 2016).
Preclinical Reproduction
Epididymal hypospermia and spermatogenic epithelial degeneration were observed after 4
weeks at 1250 mg/kg in rats, but not in doses up to 500 mg/kg. There were no changes in
sperm count, motility or morphology in monkeys at 500 mg/kg for up to 69 weeks. There
were no effects on female rat fertility when given high doses. However, male rats had
reversible decreased sperm motility and fertility at ≥ 27 times human exposure. This was
not seen in monkeys. Maternal toxicity in embryo-fetal development was seen in rats at ≥
500 mg/kg and rabbits at ≥ 250 mg/kg. Fetal toxicity was observed at 2500 mg/kg in rats
and at 1250 mg/kg in rabbits. Pregabalin was not teratogenetic in mice, rats or rabbits at 31
to 77 times the mean human exposure at 600 mg/day. Developmental toxicity in rat
offspring was observed at ≥ 5 times the mean human exposure. (Morse 2016, Morse
2016a, Pfizer 2016)
6. Adverse Reactions in Humans
The adverse events associated with pregabalin treatment were assessed in a systematic
review of 39 randomized controlled trials published between 1990 to 2010. Adverse effects
significantly associated with pregabalin were dizziness, vertigo, incoordination, balance
disorder, ataxia, diplopia, blurred vision, amblyopia, tremor, somnolence, confusional
state, disturbance in attention, thinking abnormal, euphoria, asthenia, fatigue, edema,
peripheral edema, dry mouth, constipation. The adverse events associated with the highest
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 13 of 30
relative risks (RR, 95% CI) were balance disorder (8.22, 1.75 to 38.57), euphoria (6.18,
2.76 to 13.87), incoordination (4.88, 2.18 to 10.95), ataxia (4.77, 2.77 to 8.20), and edema
(4.63, 2.15 to 9.95). In 28 of the studies, the relationship between dose and effects could be
evaluated and it was determined that adverse events first presenting at 150 mg/day were
dizziness, ataxia, somnolence, edema, and dry mouth; at 300 mg/day were vertigo,
incoordination, blurred vision, amblyopia, confusional state, disturbance in attention,
thinking abnormal, euphoria, asthenia, peripheral edema, and constipation; at 450 mg/day
were balance disorder and fatigue; and at 600 mg/day were diplopia and tremor. (Zaccara
2011)
The most commonly observed adverse events according to pre-marketing clinical trials
were mild to moderate dizziness, somnolence, peripheral edema and dry mouth. These
were seen at a rate of at least 5% and were twice the rate seen with placebo. The most
common adverse events leading to discontinuation were dizziness, somnolence, ataxia,
asthenia, confusion, headache and nausea. Adverse events were similar between women
and men. Warnings highlighted in the product monograph include peripheral edema,
weight gain and creatinine kinase elevations. (Pfizer 2016)
Adverse symptoms reported through poisoning events were summarized in a retrospective
review of records from 2002-2011 involving newer anticonvulsants from the Virginia
Poison Centre. Twenty-three cases involving pregabalin were described in which 70%
were female, with an age range of 16 to 85 years, and pregabalin doses ranging from 100 –
9,000 mg (median 2,375 mg). The clinical signs or symptoms were reported broadly to be
within neuromuscular, CNS, gastrointestinal, cardiac, blood pressure and metabolic
categories. The outcome severities were assessed as having no effect in 35% of cases, a
minor effect in 22%, a moderate effect in 44%, with no severe effects noted (i.e., death).
(Wills 2014) In addition, there are 2 published case reports of pregabalin overdose
indicating minimal clinical symptoms (Miljevic 2012 – 4.2 g ingestion, Spiller 2008 –
unknown amount). In another case report, ingestion of pregabalin 8.4 g resulted in loss of
consciousness which was treated with supportive care. (Wood 2010)
Drug Interactions
The pharmacokinetic profile of pregabalin limits the potential for pharmacokinetic
mediated drug-drug interactions (i.e., it is not metabolized and does not exhibit plasma
protein binding). In addition, pregabalin does not inhibit or induce drug metabolizing
enzymes. (Ben-Menachem 2004) The lack of interactions has been supported in published
reviews where the only interactions noted were reports that carbamazepine, phenytoin,
phenobarbital, gabapentin, and oxcarbazepine could reduce pregabalin levels 11 to 22%
(Patsalos 2013), and that pregabalin has additive effects with oxycodone on cognitive and
motor functions, and increases the effects of ethanol and lorazepam. (Ben-Menachem
2004, Patsalos 2013a)
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 14 of 30
7. Dependence Potential
A. Animal Studies
Reviews by the US Centre for Drug Evaluation and Research for Pfizer’s New Drug
Application submission indicated that preclinical studies conducted in monkeys
using a self-injection paradigm suggest that tolerance may develop to the euphoric
effects pregabalin since self-administration decreased after one week. (Bonson
2004)
B. Human Studies
Tolerance
Reviews by the US Centre for Drug Evaluation and Research for Pfizer’s New Drug
Application submission indicated that evidence from Phase2/3 clinical studies
support the development of tolerance to the euphoric effects since the euphoria
receded while patients were still taking pregabalin. (Bonson 2004)
Withdrawal
The US Centre for Drug Evaluation and Research reviewed evidence from the
Pfizer’s New Drug Application submission in 2004 and summarized the following
points which were suggestive of withdrawal symptoms and indicative of physical
dependence (Bonson 2004b):
▪ Discontinuation-emergent symptoms from short- and long-term psychiatric
studies that were more frequent in pregabalin treated patients compared to
placebo treated patients were insomnia, headache, nausea, infections, diarrhea,
and chills.
▪ Scores on the Physician’s Withdrawal Checklist in psychiatric studies were
significantly different between pregabalin and placebo groups.
▪ Analysis of two pharmacokinetic studies showed discontinuation-emergent
symptoms from pregabalin of headache, nausea and diarrhea, whereas from
placebo the reports were of accidental injury, infection, skin disorder and
ventricular extrasystoles.
The current product monograph from Pfizer Canada Inc. indicates that following
abrupt discontinuation of pregabalin in clinical studies some patients reported
symptoms of insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea. In
the adverse effects information section, information is included from a study of
patients with pain associated with spinal cord injury. A withdrawal syndrome was
reported in 4.3% of patients in the pregabalin group (n=70) at doses from 150 to
600 mg/day, with no reports in the placebo group (n=67). (Pfizer 2016) The
apparent published paper of this study describes a serious adverse event in a patient
one day following pregabalin discontinuation. The patient exhibited severe
symptoms of spasticity with impaired coordination (more severe that previous
episodes). (Siddall 2006) The monograph explicitly recommends to gradually taper
pregabalin over one week when stopping treatment. (Pfizer 2016)
Published Pfizer-funded clinical trials using a discontinuation design rather than a
placebo-control group have been conducted which incorporated a 1-week taper
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 15 of 30
when pregabalin was stopped (i.e., for those randomized from pregabalin to placebo
and at the end of the study for those taking pregabalin throughout). In general, the
adverse event rates for nausea, headache, and diarrhea did not appear to be elevated
for the placebo groups. However, treatment-emergent adverse events were reported
globally for the treatment groups and not specifically during or after the taper
periods, making interpretation of withdrawal effects difficult. (Gilron 2011, Raskin
2014, Arnold 2014)
Discontinuation symptoms associated with a 1-week taper were specifically studied
in a Pfizer-funded multi-centre, double-blind, clinical trial. (Kasper 2014) A total of
615 patients with generalized anxiety disorder were randomized to pregabalin
higher dose (450-600 mg/day), pregabalin lower dose (150-300 mg/day), or
lorazepam (3-4 mg/day). After 12 weeks of flexible dosing, 25% of patients in each
group were randomized to undergo a 1 week blinded taper and to continue placebo
for another 11 weeks, while the remainder continued on a fixed dose of active
medication for another 12 weeks. At the end of 24 weeks, all subjects underwent a
1-week taper. Anyone experiencing severe withdrawal symptoms could have the
taper period extended to 4 weeks. The primary outcome measure was the Physician
Withdrawal Checklist (PWC) which has 20 items related to anxiolytic drug
withdrawal signs and symptoms, with scores ranging from 0-60. The secondary
measure was the spontaneously reported Discontinuation-Emergent Signs and
Symptoms (DESS). Rates of rescue tapers were also reported. Measures were taken
start of taper week and 1 and 2 weeks later. The changes in the Physician Checklist
Scores from before and after the taper appear to be low, however, approximately
1/3 (range 22%-36%) of patients exhibited discontinuation-emergent signs and
symptoms during the taper, and some patients in all groups required rescue taper
procedures. The authors characterized these discontinuation symptoms as not
clinically significant. (Kasper 2014)
Summary of discontinuation symptom outcomes (Kasper 2014) Groups PWC
Mean Change* (95% CI)
% with
DESS+
Rescue Taper**
# patients Pregabalin Higher Dose – taper at 12 weeks 2.1 (0.4-3.7)
N=54 36.2% N=58
4
Pregabalin Higher Dose – taper at 24 weeks 2.8 (1.6, 3.9) N=106
31.2% N=109
6
Pregabalin Lower Dose – taper at 12 weeks 2.0 (0.5, 3.6) N=49
32.7% N=52
6
Pregabalin Lower Dose – taper at 24 weeks 1.7 (0.7, 2.8) N=84
22.3% N=94
5
Lorazepam – taper at 12 weeks 1.6 (-0.3, 3.6) N=44
32.7% N=52
2
Lorazepam – taper at 24 weeks 2.2 (1.0, 3.5) N=93
28% N=100
8
*difference between start of 1-week taper and 2 weeks later +symptoms included anxiety, dizziness, headache, insomnia and nausea
**includes patients who discontinued treatment early or entered the taper period
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 16 of 30
A withdrawal syndrome was noted in 32.7% (18/55) of pregabalin
abuse/dependence-related reports to the German Federal Institute for Drugs and
Medical Devices from 2008-2012. (Gahr 2013a)
In a review of 102 pregabalin clinical studies, none of the adverse effects described
withdrawal symptoms, although the authors comment that this may have been
influenced by the short treatment durations. (Schjerning 2016)
8. Abuse Potential
A. Animal Studies
Preclinical conditioned place preference studies in mice and self-administration or
drug discrimination studies in monkeys have yielded conflicting results, which have
been attributed to varying study conditions, including different routes of
administration. (Schjerning 2016) The US Centre for Drug Evaluation and Research
(Bosnon 2004, Throckmorten 2004) reviewed of evidence from Pfizer’s New Drug
Application submission of preclinical behavioural studies and deemed them not
valid for assessing abuse potential for a variety of reasons. However, the review
pointed out a study in monkeys (n=4) that showed pregabalin produced reinforcing
effects by demonstrating self-administration of greater than 10 injections per day at
the 3.2 and 10 mg/kg/infusion doses during initial access to the drug.
B. Human Studies
There is one published study that used an abuse liability study design to evaluate
the effects of pregabalin alone and in combination with oxycodone. (Zacny 2012)
This was a double-blind, randomized study in 16 healthy volunteers. The
participants were each administered single doses of pregabalin 75 mg, pregabalin
150 mg, oxycodone 10 mg, and pregabalin 75 mg combined with oxycodone 10 mg
in a cross-over design. Neither dose of pregabalin alone increased ratings of “like
drug” or “take drug again”. This study demonstrated low abuse liability associated
with low doses of pregabalin in people without psychiatric and substance use
disorders histories.
The US Centre for Drug Evaluation and Research (Bosnon 2004, Throckmorten
2004) reviewed evidence from Pfizer’s New Drug Application submission and
summarized a study that showed a single dose of pregabalin 450 mg administered to
alcohol or sedative/hypnotic recreational users (n=15) was rated similarly to a
single dose of diazepam 30 mg on measures of “good drug effect”, “high”, and
“liking”. A 200 mg dose of pregabalin was identified as a sedative.
In a review of 102 pregabalin clinical trials, it was reported that 14 studies indicated
euphoria as an adverse effect with a prevalence primarily between 1-10% (with one
study reporting 26%). (Schjerning 2016) These studies spanned cohorts with
fibromyalgia, painful neuropathies, postherpetic neuralgia, generalized anxiety
disorder and healthy volunteers. Many studies did not indicate explicitly whether
people with substance abuse were excluded or not. It was determined that euphoria
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 17 of 30
appeared to be a dose-dependent effect and transient effect. In addition,
endorsements of ‘feeling good’, ‘feeling dazed’, ‘being drunk’ or ‘overdosed’ were
reported in one clinical trial each. (Schjerning 2016).
9. Therapeutic Applications and Extent of Therapeutic Use and
Epidemiology of Medical Use
Pregabalin is indicated for partial onset seizures, post-herpetic neuralgia, diabetic
neuropathy, fibromyalgia, spinal cord injury neuropathic pain, and generalized anxiety
disorder. From July 2004 to March 2012, there has been an estimated 15,951,859 million
patient-years of exposure to LYRICA®. (Pfizer 2016) In England, there was a 53%
increase in pregabalin prescribing between 2011 and 2013. (PHE/NHS 2014) In Denmark,
pregabalin prescribing increased 10-fold over a 10 year period. (Schjerning 2016)
Worldwide sales of pregabalin have had an annual growth rate of approximately 12%.
(Schjerning 2016)
10. Listing on the WHO Model List of Essential Medicines
Pregabalin is not listed on the WHO Model List of Essential Medicines (20th List) or the
WHO Model List of Essential Medicines for Children (6th List).
11. Marketing Authorizations (as a Medicinal Product)
Marketing authorizations for pregabalin as a medicine are held by many companies.
Examples (not limited) are: Pliva Pliva Hrvatska, Laboratorio Chile, Abdi Ibrahim,
Andalous, Apotex, Pharos, Averroes, Ivax, Buxton, Actavis Baltics Eesti, Craveri, Al
Rowad, Debeiky, Pisa, Beta, Medley, Bioxell, Ecupharma, Actavis, Bosnalijek, AHPL,
Renata, ACI, Getz Pharma, CCL, Gast Ph, Benta, Gador, Teva, Globe, Aversi, GNP,
Amoun, Temis Lostalo, Chemi ph, Sandoz, Actavis UK, PharmaSwiss, Baliarda,
Healthcare, Elite Ph, Hikma, Roemmers, Sun Pharma, Penn Pharmaceut, Grand Pharma,
Ibn Sina, Koçak, Casasco, Square, Aristopharma, Laboratorio Saval, Icarus, Dong-A,
Zydus, Wockhardt, Invision, Innokon, Bilim, Gen, Nobel, Alpha Gp, Peerage, USV,
Eskayef, Laboratorios Raffo, Pharmascience, Krka, General Pharma, LKM, Johnlee,
Johnlee, Medicamenta Ecuatoriana, Ariston, Andic, Royal Pharma, Egpi, Alvogen, Krka,
Pfizer, Sandoz, Sanis Health, Teva Eesti, Alter, Apotex, Baldacci, Cinfa, Ecar, Farmoz,
Alter, Generis, Jaba, Kern, Kipa, MK, Pentafarma, Pharmakern, Ratiopharm, STADA,
Tarbis, Tetrafarma, Teva Pharma, ToLife, Alfred E. Tiefenbacher, Aurobindo, Centrafarm,
Hetero, Krka, Ranbaxy, Sandoz, Teva, Torrent, Wockhardt, Mepha Pharma, Gedeon
Richter, Laboratorio Tecnoquímicas, Incepta, Molekule, Crescent, Crescent, Delta,
Wörwag, ABL Pharma, ITF - Labomed Farmaceutica, AHPL, G.L. Pharma, Navana, East
West, East West, Invision, Lupin, Trend Ph, Eva, Apex, Torrent, Torrent, Little Greave,
Drugtech, Molekule, Molekule, Drug International, Tecnoquimicas, Paill, Hasan, Franco-
Indian, Franco-Indian, Laboratorio Bago, Malody, Sanofi-Aventis, Monico, Kalbe,
Ranbaxy, Ilko, Sanofi Aventis, Strides Arcolab, Orchid, Consilient Health, Sanify, Sandoz,
Serio Pharm, Sanovel, Teva Canada, FDC, Marcyrl, Novartis, and Orion.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 18 of 30
12. Industrial Use
None.
13. Non-Medical Use, Abuse and Dependence
Although still limited, there is a variety of evidence suggesting pregabalin is subjected to
non-medical use, abuse and dependence; perhaps at increasing rates.
Adverse Drug Reaction Database Reports of Abuse
▪ 6.6% (7639/115,616) of reports for pregabalin were related to
abuse/dependence/misuse from 2006-2015 in the European Medicine Agency
Spontaneous Adverse Drug Reaction Reporting System. (Chiappini 2016)
▪ 3.5% (55/1552) of reports for pregabalin were related to abuse (n=11) or dependence
(n=44) reported from 2008-2012 to the German Federal Institute for Drugs and
Medical Devices. (Gahr 2013a)
▪ 1.5% (8/521) of abuse/dependence reports were related to pregabalin from 2010-2015
in the French Pharmacovigilance Database. (Bossard 2016)
▪ 8% (16/198) of drug dependence reports were related to pregabalin (up to 2009) in the
Swedish national register of adverse drug reactions (SWEDIS). (Schwan 2010)
Drug Utilization Reviews Indicating High Dose Prescribing
▪ Of outpatients prescribed pregabalin by UK general practitioners, 1% (136/13,480)
were prescribed greater than 600 mg/day from 2004-2009. (Asomaning 2016)
▪ In Denmark, 9.6% (4090/42,520) of pregablin users were prescribed greater than 600
mg/day between 2004-2013. (Schjerning 2016a)
▪ In Sweden, 8.5% (4130-48,550) of pregabalin users were prescribed greater than 600
mg/day. (Boden 2014)
▪ In Norway in 2009, of 17,111 people using pregabalin, there was high dose use noted
of more than 10 defined daily doses (DDD) (n=25) or between 5-10 DDD (n=118).
(Landmark 2011, Schjerning 2016)
Indications of Non-Medical Use/Misuse/Abuse in Surveys/Questionnaires
▪ 0.5% (8/1500) of respondents to an online survey endorsed misuse of pregabalin. These
respondents had a lifetime prevalence of use of recreational drugs that was comparable
to national UK data. (Kapil 2014)
▪ 7% of opioid dependent patients admitted for inpatient detoxification endorsed
pregabalin misuse. (Wilens 2015)
▪ 3% (4/129) of substance use disorder population in Scotland used non-prescribed
pregabalin. (Baird 2014)
▪ 68% of polysubstance use disorder patients in the National Rehabilitation Centre
(NRC) in the United Arab Emirates endorsed using pregabalin non-medically (mean of
8.3 capsules ± 0.5 per day), particularly in the younger cohort. (Alblooshi 2016)
▪ The Swedish Poisons Information Centre was noted to have cases of intravenous
injection of crushed pregabalin tablets (number not reported). (Jonsson 2014)
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 19 of 30
Postmortem Toxicology Associated with Abuse
▪ 2.3% (316/13,766) of all toxicologically investigated medico-legal cases from 2010-
2011 in Finland had pregabalin involved. 48% (152/316) of pregabalin cases were
attributed to abuse. (Hakkinen 2014)
▪ 4.4% (43/982) of all postmortem toxicology cases in Germany had pregabalin detected
from 2010-2012. In the first year studied the rate was 2% (10/489), whereas by the
second year it had substantially increased to 6.7% (33/493). Within drug dependent
individuals the rate went from 5.5% (4/72) to 29.8% (26/87) over the 2 year period.
(Lottner-Nau 2013)
▪ 4.2% (68/1623) of deceased young adults had pregabalin detected over a 3 year period
in Finland. (Launiainen 2011)
Detection in Urine Drug Screening in Opioid Dependent Populations
▪ 9.2% (39/425) of urine samples from opioid dependence treatment patients tested
positive for pregabalin over a 3 month period in 2014 in Ireland, with only 10 patients
prescribed the medication. (McNamara 2015)
▪ 12.1% (15/124) of urine samples from opioid dependence treatment patients tested
positive for pregabalin, compared to 2.7% (3/111) in a cohort of patients with other
substance use disorders. (Grosshans 2013)
Case Reports of Abuse
▪ A systematic review (Schjerning 2016) identified 10 case reports starting in 2010
describing pregabalin abuse-related events according to ACTTION definitions. (Smith
2013) These cases involved supra-therapeutic dosing (n=10 with highest 2400 mg
single dose, range 800-7500mg), diversion (n=3), tampering (n=1), and withdrawal
symptoms (n=2). The people involved had a mean age of 34 years (range 19-47), 6
men and 4 women, 2 had no history of substance abuse, one case had nicotine use
only, and most (n=8) had psychiatric diagnoses, primarily mood and anxiety disorders
or personality disorders. (Schjerning 2016)
▪ Of 30 heroin users interviewed in a treatment service setting in the UK, 19 were
pregabalin users (n=1 daily user, n=3 weekly, n=5 rarely, n=10 once), doses reported
from 300 to 1500mg, prescribed or purchased on the street. (Lyndon 2017)
Anecdotal Online Reports
▪ Qualitative Google searches in 8 European languages of 108 websites were conducted
on a regular basis between 2008 and 2010 documenting posts related pregabalin
recreational use. From these anecdotal reports, the authors noted that primarily high
doses of pregabalin (up to 5 g) were used for the euphoric effects, effects similar to
alcohol, benzodiazepines and GHB, to cope with opioid withdrawal, and for
entactogenic feelings or dissociative effects. Pregabalin was mostly used orally, but
also by injection or rectally. Tolerance developed rapidly leading to increasing
dosages and recommendations to combined use with other sedatives. Tolerance was
also lost quickly once use ceased. (Schifano 2011)
Self-reported Street Prices
▪ Based on self-reported information (via website submission) on street prices of
diverted prescription drugs, prices for pregabalin per pill have ranged from $3-5 in the
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 20 of 30
United States, $6 in Canada, £0.05-150 in United Kingdom, €2-3 in Germany and
$<1-$150 in Australia. (Streetrx.com)
▪ Heroin users interviewed in a treatment service setting in the UK who had purchased
pregabalin on the street reported paying approximately £2 per 300 mg tablet. (Lyndon
2017)
Advice for Clinicians
There have been practice guidance documents produced for clinicians reflecting the
concern and growing awareness of pregabalin’s abuse potential. For example:
▪ In Ireland a guidance document has been produced for clinicians entitled “Pregabalin
– Guidance for people working with pregabalin users. How to reduce the risks.” The
document explains what pregabalin is, features of recreational use and harm
reductions strategies. (Extern 2017)
▪ In the UK, the NHS produced a document on “Prescribing advice for Pregabalin”
which recommends that clinicians be aware of the risk of abuse and addiction to
pregabalin, even in patients with no known history of abuse; and consider the street
value of the drug. (NHS 2017)
▪ Also in the UK, a document was developed to provide advice for prescribers on the
risk of the misuse of gabapentin and pregabalin. PHE and NHS England (2014)
Literature Reviews
▪ Evoy 2017 – USA. Systematic Review key points: growth of epidemiological studies;
abuse appears to be more prevalent in opioid abusers; supratherapeutic doses typically
needed to achieve euphoria.
▪ Schjerning 2016 – Denmark. Systematic Review key points: literature suggest an
important abuse potential; prescribers need to be cautious when prescribing,
particularly to patients with a substance use history, and look for signs of abuse.
▪ Schifanao 2014 – UK. Review key Points: Pregabalin experimenters are those with a
recreational drug histories, administering excessive dosages; physician need to assess
for history of substance use.
▪ CADTH 2012 – Canada. Systematic Review key points: Further
psychopharmacological studies are needed to assess pregabalin abuse liability across a
range of doses in sedative abusers, and in combination with other CNS-active drugs.
14. Nature and Magnitude of Public Health Problems Related to Misuse,
Abuse and Dependence
Overdose
There is a case series describing 10 patients admitted to an Emergency Department in
Belfast over a one year period with pregabalin abuse. All were between 20-35 years old,
with dosages ranging from 500-1400 mg. Nine were admitted for over 24 hours, 6 patients
had seizures, and 2 patients were admitted to the Intensive Care Unit. (Millar 2013)
Pregabalin levels were determined in 70 postmortem cases from a 2 year period in the
United Kingdom. They attributed one death to pregabalin toxicity with a concentration of
76 mg/L. Although the majority of the people had been prescribed pregabalin, other drugs
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 21 of 30
were present in all samples. In several cases, death was attributed to multiple drug toxicity
involving opioids and other drugs of abuse. (Eastwood 2016)
In a review of 93 postmortem cases, 9 of them were determined to have pregabalin
contribute to death. The authors comment that the prevalence of methadone and other
opioids in these cases raises the profile of pregabalin as a drug with the potential for abuse,
and recommends that laboratories include pregabalin in their protocols. (Elliot 2017)
In the United Kingdom and Wales there has been an increase of 24% each year in the
number of gabapentoid (pregabalin and gabapentin) prescriptions from 2004 to 2015,
which has been highly correlated with an increase in deaths where a gabapentoid was
mentioned on the death certificate (correlation coefficient 0.96). (Lyndon 2017) In 79% of
these deaths opioids were also mentioned.
Driving
In one study, pregabalin did not interfere with simulated driving ability after 2 doses of 75
mg compared to placebo in healthy volunteers. (Tujii 2014)
In 2012, 206 drivers in Finland who were apprehended for driving under the influence had
pregabalin detected in serum samples at concentrations ranging from 0.68 – 111.6 mg/L.
Over half of the samples were deemed to be above a therapeutic range, suggesting use for
recreational purposes. Interpretation is difficult however since in most cases the driver had
also taken other drugs. (Kriikku 2014)
Pregabalin and Opioids
In light of the frequency of references to pregabalin use in combination with opioids,
particularly cases of overdose death, there are a potential public health implications.
Therefore, understanding the nature of the combined effects is important.
In a study evaluating the respiratory effects of pregabalin and morphine together in mice,
the combination produced additive depression of respiration (rather than synergistic). In
addition, when pregablin was administered to morphine tolerant mice, pregabalin appeared
to reverse the tolerance to respiratory depression. The authors comment that these findings
support the suggestion that the combination increases the risk of overdose death. (Lyndon
2017)
In a series of preclinical studies, mice were more sensitive to sedation by pregabalin in the
context of chronic morphine exposure, without evidence of rewarding effects from
pregabalin. The study also showed that pregabalin may attenuate both morphine self-
administration and morphine withdrawal signs. (Vashchinkina 2017)
In the abuse liability study by Zacny et.al., (2012) the hypothesis was that pregabalin
would potentiate oxycodone’s abuse liability. The combination of pregabalin 75 mg and
oxycodone 10 mg increased the endorsement of “take drug again’ whereas neither drug
alone did. However, since the drug combination also produced negative effects (headaches)
the authors concluded that the study did not support the hypothesis at these doses.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 22 of 30
Pregabalin’s effects on opioid withdrawal symptoms was studied in a small randomized,
controlled trial in 34 opioid dependent participants undergoing opioid withdrawal. Patients
receiving pregabalin 600mg/day over 6 days had better treatment retention compared to
those receiving clonidine 600 μg/day (79% vs 47%, respectively), had lower opioid craving
scores (p=0.03) and lower depression scores (p=0.2), with similar opioid withdrawal
severity. (Vashchinkina 2017)
15. Licit Production, Consumption and International Trade
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances.
16. Illicit Manufacture and Traffic and Related Information
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances.
17. Current International Controls and Their Impact
Pregabalin is not controlled under the 1961, 1971 or 1988 United Nations Conventions.
18. Current and Past National Controls
In July 2005, the United States Drug Enforcement Administration (DEA) placed pregabalin
and all products containing pregabalin into Schedule V of the Controlled Substances Act
(CSA). (Drug Enforcement Administration 2005)
In the United Kingdom, the Advisory Council on the Misuse of Drugs recommended that
pregabalin be controlled under the Misuse of Drugs Act 1971 as Class C substances, and
scheduled under the Misuse of Drugs Regulations 2001 (as amended) as Schedule 3, so as
not to preclude legitimate use on prescription. (Iverson 2016).
19. Other Medical and Scientific Matters Relevant for a Recommendation on
the Scheduling of the Substance
None.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 23 of 30
References
AHFS DI Essentials. © Copyright 2017, Selected Revisions October 3, 2014. American Society of
Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland
20814.
Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, et al. The pattern
of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation
Centre cohort study. Subst Abuse Treat Prev Policy. 2016;11:19.
ARK™ Pregabalin Urine Assay.2015.
Arnold LM, Arsenault P, Huffman C, Patrick JL, Messig M, Chew ML, Sanin L, Scavone JM,
Pauer L, Clair AG. Once daily controlled-release pregabalin in the treatment of patients with
fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr
Med Res Opinion. 2014;30(10):2069-83.
Asomaning K, Abramsky S, Liu Q, Zhou X, Sobel RE, Watt S. Pregabalin prescriptions in the
UK: a drug utilization study of The Health Improvement Network (THIN) primary care database.
Int J Clin Pract. 2016;70(5):380–8.
Baird CR, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone:
a survey among substance misusers. Eur Addict Res. 2014;20(3):115–8.
Bali A, Gaur P. A novel method for spectrophotometric determination of pregabalin in pure form
and in capsules. Chem Cent J. 2011;5:59.
Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia
2004;45(suppl 6):13-18.
Biermann T, Bleich S, Kornhuber J, Hillemacher T. Pregabalin in benzodiazepine withdrawal.
Pharmacopsychiatry. 2007 Nov;40(6):292-3.
Bobes J, Rubio G, Teran A, Cervera G, Lopez-Gomez V, Vilardaga I, et al. Pregabalin for the
discontinuation of long term benzodiazepines use: an assessment of its effectiveness in daily
clinical practice. Eur Psychiatry. 2012;27(4):301–7.
Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch J, Randinitis EJ,
Corrigan BW, Haig GM, Boyd RA, Wesche DL. Clinical pharmacokinetics of pregabalin in health
volunteers. Journal of Clinical Pharmacology 2010;50:941-950.
Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin dispensing at
higher than the approved maximum dose. Eur J Clin Pharmacol. 2014;70(2):197–204.
Bonson 2004. Center for Drug Evaluation and Research. (2004). Pharmacology Review. In: Lyrica
(pregabalin) capsules. Application No.:21-446 (FDA drug approval package). Retrieved from
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021724s000_PharmR.pdf
Accessed Sept 15, 2017.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 24 of 30
Bossard JB, Ponte C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality analysis for
the assessment of abuse and dependence potential of pregabalin in the French pharmacovigilance
database. Clin Drug Investig. 2016. (Epub ahead of print).
Bramness JG, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica®) help patients
reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian
Prescription Database. Basic Clin Pharmacol Toxicol. 2010;107(5):883–6.
Burk MJ, de Koning PD, Grote TM, Hoekstra MS, Hoge G, Jennings RA, Kissel WS, Le TV,
Lennon IC, Mulhern TA, Ramsden JA, Wade RA. An Enantioselective Synthesis of (S)-(+)-3-
Aminomethyl-5-methylhexanoic Acid via Asymmetric Hydrogenation. J Org Chem.
2003;68:5731-4.
CADTH. Abuse and misuse potential of pregabalin: A review of the clinical evidence. Rapid
Response Report: Summary with Critical Appraisal. Canadian Agency for Drugs and
Technologies in Health. April 2012. https://www.cadth.ca/media/pdf/htis/april-
2012/RC0348%20Pregabalin%20draft%20report%20Final.pdf
Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking
allegations, and possible association with myositis: two case reports. J Clin
Psychopharmacol.2012;32(6):839–40.
ChemSpider. http://www.chemspider.com/Chemical-Structure.4589156.html. Accessed Sept 7,
2017.
Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European
Medicines Agency’s ‘Suspected Adverse Drug Reactions’ database. CNS Drugs. 2016. (Epub
ahead of print).
Cho YW, Song ML. Effects of pregabalin in patients with hypnotic-dependent insomnia. J Clin
Sleep Med. 2014;10(5):545–50.
Drug Enforcement Administration, Department of Justice. Schedules of controlled substances:
placement of pregabalin into schedule V. Final rule. Fed Regist. 2005;70(144):43633-5.
Drugs.com. https://www.drugs.com/international/pregabalin.html Accessed Sept 7, 2017
DRUGS.ie Pregabalin Fact Sheet.
http://www.drugs.ie/downloadDocs/2017/Pregabalin%20FactSheet%20Revision%20-%204.pdf.
Accessed Sept 7, 2017
Eastwood JA, Davison E. Pregabalin concentrations in post-mortem blood—a two year study.
Forensic Sci Int. 2016;266:197–201.
Elliott SP, Burke T, Smith C. Determining the toxicological significance of pregabalin in fatalities.
J Forensic Sci. 2017 Jan;62(1):169-173.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 25 of 30
Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs.
2017; DOI 10.1007/s40265-017-0700-x.
Extern. Pregabalin. Guidance for people working with pregabalin users. Ireland.
http://www.extern.org/news/extern-publishes-new-guidance-booklet-people-working-pregabalin-
lyrica%C2%AE-users Accessed Sept 7, 2017
Filipetto FA, Zipp CP, Coren JS. Potential for pregabalin abuse or diversion after past drug-
seeking behavior. J Am Osteopath Assoc. 2010;110(10):605–7.
Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, Behar R. Pregabalin for the
Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review. CNS Drugs.
2016 Dec;30(12):1191-1200.
Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and
dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013a;69(6):1335–
42.
Gahr M, Franke B, Freudenmann RW, Kolle MA, Schonfeldt-Lecuona C. Concerns about
pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med.
2013b;7(2):147–9.
Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for Peripheral Neuropathic Pain:
A Multicenter, Enriched Enrollment Randomized Withdrawal Placebo-controlled Trial. Clin J
Pain. 2011;27:185-93.
Grosshans M, Lemenager T, Vollmert C. Pregabalin abuse among opiate addicted patients. Eur J
Clin Pharmacol. 2013;69(12): 2021–5.
Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, et al. Pregabalin abuse,
dependence, and withdrawal: a case report. Am J Psychiatry. 2010;167(7):869.
Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to
pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J
Psychopharmacol. 2012 Apr;26(4):461-70.
Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin
abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6.
Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf.
2015;10(2):184–6.
Heltsley R, Depriest A, Black DL, Robert T, Caplan YH, Cone EJ. Urine drug testing of chronic
pain patients. IV. Prevalence of gabapentin and pregabalin. J Anal Toxicol. 2011;35(6):357-9.
Iversen. Pregabalin and Gabapentin Advice. Advisory Council on the Misuse of Drugs, Jan 14,
2016. https://www.gov.uk/government/publications/advice-on-the-anticonvulsant-drugs-
pregabalin-and-gabapentin Accessed Sept 7, 2017
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 26 of 30
Jonsson B, Backman E, Salmonson H, Hojer J. Injection of crushed tablets – a prospective
observational study. Clinical Toxicology 2014;52:982-983.
Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the c-aminobutyric acid
analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78(1):190–1.
Kasawar GB, Farooqui MN. Development and Validation of HPLC Method for the Determination
of Pregabalin in Capsules. Indian J Pharm Sci. 2010;72(4):517–9.
Kasper S, Iglesias-García C, Schweizer E, Wilson J, DuBrava S, Prieto R, Pitman VW, Knapp L.
Pregabalin long-term treatment and assessment of discontinuation in patients with generalized
anxiety disorder. Int J Neuropsychopharmacol. 2014 May;17(5):685-95.
Kriikku P, Wilhelm L, Rintatalo J, Hurme J, Kramer J, Ojanperä I. Pregabalin serum levels in
apprehended drivers. Forensic Sci Int. 2014 Oct;243:112-6.
Landmark CJ, Fossmark H, Larsson PG, Rytter E, Johannessen SI. [The prescription registry and
abuse of pregabalin]. Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):223.
Launiainen T, Broms U, Keskitalo-Vuokko K, Pitkaniemi J, Pelander A, Kaprio J, et al. Nicotine,
alcohol, and drug findings in young adults in a population-based postmortem database. Nicotine
Tob Res. 2011;13(9):763–71.
Lottner-Nau S, Ovguer B, Paul LD, Graw M, Sachs H, Roider G. Abuse of pregabalin—results of
the postmortem toxicology from 2010–2012. Toxichem Krimtech. 2013;80:339.
Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, Hickman M, Henderson G. Risk to
heroin users of polydrug use of pregabalin or gabapentin. Addiction. 2017 Sep;112(9):1580-1589.
McNamara S, Stokes S, Kilduff R, Shine A. Pregabalin abuse amongst opioid substitution
treatment patients. Ir Med J. 2015;108(10):309–10.
Miljevic CD, Crnobaric C, Nikolic S, Lecic-Tosevski D. A case of pregabalin intoxication.
Psychiatriki. 2012;23(2):162–5
Millar J, Sadasivan S, Weatherup N, Lutton S. Lyrica nights–recreational pregabalin abuse in an
urban emergency department. Emery Med J. 2013;30:874.
Morse DC. Embryo-fetal developmental toxicity studies with pregabalin in mice and rabbits. Birth
Defects Res B Dev Reprod Toxicol. 2016 Apr;107(2):85-93.
Morse DC, Henck JW, Bailey SA. Developmental toxicity studies with pregabalin in rats:
Significance of alterations in skull bone morphology. Birth Defects Res B Dev Reprod Toxicol.
2016 Apr;107(2):94-107.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 27 of 30
NHS 2017. In Focus: Pregabalin. Prescribing advice for pregabalin.
http://www.dorsetccg.nhs.uk/Downloads/aboutus/medicines-
management/Other%20Guidelines/In%20Focus-Pregabalin.pdf (Accessed Sept 2017)
PHE and NHS England (2014) Advice for prescribers on the risk of the misuse of gabapentin and
pregabalin www.gov.uk/government/uploads/system/uploads/attachment_data/file/385791/PHE-
NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf
Oertel R, Arenz N, Pietsch J, Kirch W. Simultaneous determination of three anticonvulsants using
hydrophilic interaction LC–MS. J Sep Sci. 2009;32(2):238–43.
Oulis P, Masdrakis VG, Karakatsanis NA, Karapoulios E, Kouzoupis AV, Konstantakopoulos G,
Soldatos CR. Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. Int
Clin Psychopharmacol. 2008a Mar;23(2):110-2.
Oulis P, Konstantakopoulos G, Kouzoupis AV, Masdrakis VG, Karakatsanis NA, Karapoulios E,
Kontoangelos KA, Papadimitriou GN. Pregabalin in the discontinuation of long-term
benzodiazepines' use. Hum Psychopharmacol. 2008b Jun;23(4):337-40.
Papazisis G, Garyfallos G, Sardeli C, Kouvelas D. Pregabalin abuse after past substance-seeking
behavior. Int J Clin Pharmacol Ther. 2013;51(5):441–2.
Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)—Part 2:
pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-
epilepsy disorders. Clin Pharmacokinet. 2013 Dec;52(12):1045-61.
Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)—part 1:
pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013
Nov;52(11):927-66.
Pfizer Canada Inc. Lyrica® Product Monograph. December 6, 2016.
http://www.pfizer.ca/sites/g/files/g10028126/f/201612/LYRICA_DC_PM_198215_6Dec2016_E.p
df Accessed September 7, 2017.
Pfizer UK 2017. Lyrica Capsules. http://www.medicines.org.uk/emc/print-
document?documentId=14651 Accessed Sept 7, 2017.
.
Pfizer USA Lyrica. December 2016. http://labeling.pfizer.com/showlabeling.aspx?id=561
Accessed Sept 7, 2017.
Priez-Barallon C, Carlier J, Boyer B, Benslima M, Fanton L, Mazoyer C, Gaillard Y.
Quantification of Pregabalin Using Hydrophilic Interaction HPLC-High-Resolution MS
in Postmortem Human Samples: Eighteen Case Reports. J Analytical Toxicol. 2014;38:143–8.
Raskin P, Huffman C, Toth C, Asmus MJ, Messig M, Sanchez RJ, Pauer L. Pregabalin in patients
with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial.
Clin J Pain. 2014 May;30(5):379-90.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 28 of 30
Schifano F. Misuse and abuse of pregabalin and gabapentin: Cause for concern? CNS Drugs
2014;28:491-496.
Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse potential of pregabalin.
A systematic review. CNS Drugs 2016;30:9-25.
Schjerning O, Pottegard A, Damkier P, Rosenzweig M, Nielsen J. Use of pregabalin—a
nationwide pharmacoepidemiological drug utilization study with focus on abuse potential.
Pharmacopsychiatry. 2016a. (Epub ahead of print).
Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in
the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013;9(1):105-15.
Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for
pregabalin–results from the Swedish spontaneous adverse drug reaction reporting system. Eur J
Clin Pharmacol. 2010;66(9):947–53.
Siddall PJ, Cousins MJ, Otte A, Griesing T, Chambers R, Murphy TK. Pregabalin in central
neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurology.
2006;67:1792-1800.
Silverman RB. From Basic Science to Blockbuster Drug: The Discovery of Lyrica. Angew Chem
Int Ed. 2008;47:3500-4.
Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR,
Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya I, O’Brien C,
Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH.
Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION
systematic review and recommendations. Pain. 2013;154:2287–96.
Spiller HA, Bratcher R, Griffith JR. Pregabalin overdose with benign outcome. Clin Toxicol
(Phila). 2008;46(9):917.
Stahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A. The diverse therapeutic actions of
pregabalin: is a single mechanism responsible for several pharmacological activities?. Trends in
Pharmacol Sci. 2013;34(6):332-9.
Streetrx.com (accessed October 17, 2017). RADARS StreetRx Program.
http://www.radars.org/home2/programs/streetrx
Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The
calcium channel 2—(alpha2—delta) subunit as a target for antiepileptic drug discovery. Epilepsy
Research. 2007;73:137-50.
Throckmorten 2004 Center for Drug Evaluation and Research. (2004). Medical review(s). In:
Lyrica (pregabalin) capsules. Application No.:21-446 (FDA drug approval package). Retrieved
from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_Lyrica
Capsules_medr.pdf Accessed Sept 15, 2017.
39th ECDD (2017) Agenda item 5.1 Pregabalin
Page 29 of 30
Tujii T, Kyaw WT, Iwaki H, Nishikawa N, Nagai M, Kubo M, Nomoto M. Evaluation
of the effect of pregabalin on simulated driving ability using a driving simulator in healthy male
volunteers. Int J Gen Med. 2014 Jan 29;7:103-8.
Vashchinkina E, Piippo O, Vekovischeva O, Krupitsky E, Ilyuk R, Neznanov N, Kazankov K,
Zaplatkin I, Korpi ER. Addiction-related interactions of pregabalin with morphine in mice and
humans: reinforcing and inhibiting effects. Addiction Biology. 2017; doi:10.1111/adb.12538.
Vermeij TAC, Edelbroek PM. Simultaneous high-performance liquid chromatographic analysis of
pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-
phtaldialdehyde and fluorescence detection. J Chromatogr B. 2004;810(2):297–303.
Warner G, Figgitt DP. Pregabalin as adjunctive treatment of partial seizures. CNS Drugs
2005:19(3):265-272.
Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse
among opioid dependent patients seeking inpatient detoxification. Am J Addict.
2015;24(2):173–7.
Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, et al. Clinical outcomes in
newer anticonvulsant overdose: a poison center observational study. J Med Toxicol.
2014;10(3):254–60.
Wood DM, Berry DJ, Glover G, Eastwood J, Dargan PI. Significant pregabalin toxicity managed
with supportive care alone. J Med Toxicol. 2010;6(4):435–7.
Yu HJ, Shao C, Cui Z, Feng CG, Lin GQ. Highly Enantioselective Alkenylation of Cyclic a,b-
Unsaturated Carbonyl Compounds as Catalyzed by a Rhodium–Diene Complex: Application to
the Synthesis of (S)-Pregabalin and ()-a-Kainic Acid. Chem Eur J. 2012;18:13274–8.
Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a
systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52(4):826-
836.
Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of
pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem
Behav. 2012;100(3):560–5.